Salvador Guardiola

Has grant

Head of Protein Science

ONA Therapeutics

Spain

Research Interests

Explore related searches

Professors in Spain Professors in Immunology Immunology professors in Spain

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Salvador Guardiola is the Head of Protein Science at ONA Therapeutics in Spain. His research focuses on the characterization of novel peptides with antimicrobial and anticancer properties, alongside utilizing advanced proteomic tools for drug development. Recent publications include work on cathelicidin-based peptides and the exploration of anti-EGF nanobodies in non-small cell lung cancer models.

Recent Grants

Grant: Close

Supporting transnational mobility within the European life sciences by cofunding of the EMBO Fellowship Programme

Open Date: 2014-11-10

Close Date: 2018-08-09

Articles (9)

Year:

2025

Year:

2024

Year:

2024

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Collaborators (1)

Davia Prischich

University of Oxford

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Salvador Guardiola

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (9)

In Vitro and In Vivo Characterization of Novel Cathelicidin-Based Peptides with Antimicrobial Activity Against Pseudomonas aeruginosa

In vivo photocontrol of orexin receptors with a nanomolar light-regulated analogue of orexin-B

Angiotensin-(1-9) Retro-Enantiomer Peptide With Cardioprotective Activity

Anti-EGF nanobodies enhance the antitumoral effect of osimertinib and overcome resistance in non-small cell lung cancer (NSCLC) cellular models

A new synthetic protegrin as a promising peptide with antibacterial activity against MDR Gram-negative pathogens

Proteomic Tools for the Quantitative Analysis of Artificial Peptide Libraries: Detection and Characterization of Target‐Amplified PD‐1 Inhibitors

Abstract 1839: Nanobodies against EGF enhance the antitumoral effect of osimertinib and overcome resistance in non-small cell lung cancer cell models

Target-templated de novo design of macrocyclic d-/l-peptides: discovery of drug-like inhibitors of PD-1

Probing the Kinetic and Thermodynamic Fingerprints of Anti-EGF Nanobodies by Surface Plasmon Resonance

Collaborators (1)

Davia Prischich

Make your next move.